Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-01
2008-07-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C514S035000, C536S004100, C536S017400, C536S018100
Reexamination Certificate
active
11247356
ABSTRACT:
The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula:wherein R represents a hydrogen atom, a lower alkyl group or a group forming a prodrug; one of Q and T represents agroup represented by the general formula:(wherein P represents a hydrogen atom or a group forming a prodrug), while the other represents a lower alkyl group or a halo(lower alkyl) group; R2represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom; and with the proviso that P does not represent a hydrogen atom when R represents a hydrogen atom or a lower alkyl group, or pharmaceutically acceptable salts thereof, which exert an inhibitory activity in human SGLT2 and have an improved oral absorption, and therefore are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.
REFERENCES:
patent: 5264451 (1993-11-01), Kees
patent: 5424406 (1995-06-01), Tsujihara et al.
patent: 6683056 (2004-01-01), Washburn et al.
patent: 6815428 (2004-11-01), Ohsumi et al.
patent: 2003/0087843 (2003-05-01), Washburn
patent: 2004/0006025 (2004-01-01), Ohsumi et al.
patent: 2004/0063646 (2004-04-01), Fujikura et al.
patent: 2005/0043249 (2005-02-01), Ohsumi et al.
patent: 0 449 699 (1991-10-01), None
patent: WO 01/16147 (2001-08-01), None
patent: WO 02/036602 (2002-10-01), None
patent: WO 02/053573 (2002-11-01), None
patent: WO 03/020737 (2003-03-01), None
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
New Potent Antihyperglycemic Agents in db/db Mice: Synthesis and Structure-Activity Relationship Studies of (4-Substituted benzyl)(trifluoromethyl) pyrazoles and -pyrazolones; J. Med. Chem. 1996, 39, 3920-2938.
Harold E. Lebovitz, MD; Stepwise and Combination Drug Therapy for the Treatment of NIDDM; Diabetes Care, vol. 17, No. 12, Dec. 1994; pp. 1542-1544.
Nigishi Hotta; Chronic Disease, vol. 6, No. 1, pp. 97-102 (1995).
Nigishi Hotta, Tonyobyo Update 10, pp. 68-77 (1994).
Cecilia A. Hofmann, PhD, et al; New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers; Diabetes Care, vol. 15, No. 8, Aug. 1992; pp. 1075-1078.
Gareth Williams; Management of non-insulin-dependent diabetes mellitus; The Lancet; vol. 343; Jan. 8, 1994; pp. 95-100.
C. Ronald Kahn, M.D., et al; Joslin's Diabetes Mellitus; 13thEdition; pp. 508-509, 1994.
Harold E. Lebovits, MD; Stepwise and Combination Drug Therapy for the Treatment of NIDDM; Diabetes Care, vol. 17, No. 12, Dec. 1994; pp. 1542-1544.
Fujikura Hideki
Fushimi Nobuhiko
Isaji Masayuki
Nakabayashi Takeshi
Nishimura Toshihiro
Jiang Shaojia Anna
Kissei Pharmaceutical Co. Ltd.
McIntosh III Traviss C.
LandOfFree
Glucopyranosyloxypyrazole derivatives and use thereof in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucopyranosyloxypyrazole derivatives and use thereof in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucopyranosyloxypyrazole derivatives and use thereof in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3949459